Document Classification

Section Type: RESULTS

Text: The mean (+ / - SD) serum concentration of insulin-like growth factor I (IGF-I) decreased from base line by 4. 0 + / -16. 8 percent in the placebo group, 26. 7 + / -27. 9 percent in the group that received 10 mg of pegvisomant per day, 50. 1 + / -26. 7 percent in the group that received 15 mg of pegvisomant per day, and 62. 5 + / -21. 3 percent in the group that received 20 mg of pegvisomant per day (P < 0. 001 for the comparison of each pegvisomant group with placebo), and the concentrations became normal in 10 percent, 54 percent, 81 percent, and 89 percent of patients, respectively (P < 0. 001 for each comparison with placebo).